Govt. receives 215 applications for the 36 products under PLI scheme
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
PEL will explore the PLI scheme and apply if its beneficial.
Subscribe To Our Newsletter & Stay Updated